Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of "Buy" by Brokerages

Key Points

• Dianthus Therapeutics has a consensus analyst rating of "Buy" from 14 brokerages, with an average 12-month price target of about $117.82.
• Several firms recently boosted their outlooks, including Truist Financial, Raymond James, Wedbush, Wolfe Research, and Robert W. Baird, with price targets ranging from $98 to $132.
• The company reported a quarterly loss of ($0.85) per share, beating estimates, while insiders have sold shares recently and the stock is trading near its 52-week high.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) has been assigned a consensus recommendation of "Buy" from the fourteen brokerages that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, eleven have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $117.8182.

Several equities research analysts have commented on the stock. Wedbush upped their target price on shares of Dianthus Therapeutics from $103.00 to $105.00 and gave the company an "outperform" rating in a research note on Wednesday, May 6th. Truist Financial upped their target price on shares of Dianthus Therapeutics from $63.00 to $110.00 and gave the company a "buy" rating in a research note on Monday, March 9th. Raymond James Financial raised shares of Dianthus Therapeutics from an "outperform" rating to a "strong-buy" rating and upped their target price for the company from $63.00 to $123.00 in a research note on Tuesday, March 10th. Wolfe Research started coverage on shares of Dianthus Therapeutics in a research note on Thursday, April 9th. They issued an "outperform" rating and a $98.00 target price for the company. Finally, Robert W. Baird boosted their target price on Dianthus Therapeutics from $67.00 to $132.00 and gave the company an "outperform" rating in a research note on Tuesday, March 10th.

Insiders Place Their Bets

In other Dianthus Therapeutics news, EVP Ryan Savitz sold 114,367 shares of Dianthus Therapeutics stock in a transaction that occurred on Tuesday, March 31st. The shares were sold at an average price of $83.00, for a total value of $9,492,461.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Marino Garcia sold 122,918 shares of Dianthus Therapeutics stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $81.49, for a total transaction of $10,016,587.82. The SEC filing for this sale provides additional information. Insiders sold a total of 323,021 shares of company stock valued at $26,564,008 in the last three months. Insiders own 3.02% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Raymond James Financial Inc. bought a new position in Dianthus Therapeutics in the second quarter valued at approximately $27,000. First Horizon Corp acquired a new stake in shares of Dianthus Therapeutics in the 1st quarter valued at about $32,000. Parkside Financial Bank & Trust raised its stake in shares of Dianthus Therapeutics by 131.7% in the 3rd quarter. Parkside Financial Bank & Trust now owns 950 shares of the company's stock valued at $37,000 after purchasing an additional 540 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Dianthus Therapeutics in the 4th quarter valued at about $40,000. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Dianthus Therapeutics in the 3rd quarter valued at about $64,000. Institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Trading Up 0.1%

NASDAQ:DNTH opened at $86.84 on Monday. Dianthus Therapeutics has a 1-year low of $16.64 and a 1-year high of $96.50. The business's 50-day moving average price is $81.01 and its two-hundred day moving average price is $56.30. The firm has a market capitalization of $4.75 billion, a price-to-earnings ratio of -21.03 and a beta of 1.18.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.22. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%.The firm had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.40 million. Sell-side analysts predict that Dianthus Therapeutics will post -3.91 earnings per share for the current year.

Key Stories Impacting Dianthus Therapeutics

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Dianthus Therapeutics and set a $130 price target, suggesting meaningful upside from current levels.
• Positive Sentiment: The firm raised several earnings estimates for Dianthus Therapeutics, including FY2026 EPS to ($4.81) from ($6.21) and FY2027 EPS to ($5.49) from ($6.04), which may be viewed as improved outlook revisions.
• Neutral Sentiment: HC Wainwright also updated quarterly EPS forecasts for Q2 2026, Q3 2026, Q4 2026, and multiple 2027 quarters, but these remain negative EPS estimates as the company is still expected to be unprofitable.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.